Analyst Reco. Vaxart, Inc.

Equities

VXRT

US92243A2006

Real-time Estimate Cboe BZX Other stock markets 15:32:46 29/04/2024 BST			5-day change	1st Jan Change
0.732 ^USD	+3.14%		-4.28%	+27.43%

03-14	Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-14	Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

B. Riley Upgrades Vaxart to Buy From Neutral, Lifts PT to $2 From $1.50	01-31	MT
Cantor Fitzgerald Adjusts Price Target on Vaxart to $4 From $6, Maintains Overweight Rating	07/08/23	MT
B. Riley Lowers Vaxart's PT to $1.50 From $6, Reflecting More Conservative Estimate of Ramp-up of Norovirus; Keeps Neutral Rating	19/12/22	MT
Cantor Fitzgerald Adjusts Vaxart's Price Target to $8 From $11, Reiterates Overweight Rating	02/09/22	MT
B. Riley Trims Vaxart's Price Target to $6 from $7 to Reflect Modest Increased Long Term Cost of Capital Amid Current Macro Conditions; Keeps Neutral Rating	19/05/22	MT
B. Riley Lowers Vaxart's Price Target to $7 from $9 to Reflect Long Term Higher Cost of Capital Amid Current Macro Conditions, Keeps Neutral Rating	07/03/22	MT
Jefferies Analyst Starts Vaxart at Buy, Adjusts Price Target to $12 From $13	29/12/21	MT
Cantor Fitzgerald Starts Vaxart at Overweight With $15 Price Target	02/11/21	MT
VAXART : B. Riley Downgrades Vaxart to Neutral from Buy, Lowers PT to $9 from $13 on 'Underwhelming' Immunogenicity Dataset, Challenging Near-term Catalyst Setup	30/06/21	MT
VAXART : Jefferies Initiates Coverage on Vaxart With Buy Rating, $13 Price Target	24/06/21	MT
Vaxart : Shares Jump After Piper Sandler Starts Coverage With Overweight Rating	11/06/21	MT
VAXART : Piper Sandler Starts Vaxart at Overweight With $18 Price Target	11/06/21	MT
VAXART : B. Riley Lowers Vaxart's Price Target to $13 from $16, Keeps Buy Rating	04/03/21	MT
VAXART : B. Riley Adjusts Vaxart PT to $16 From $22, Maintains Buy Rating	18/11/20	MT
Vaxart, Inc. Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study	01/02/18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer